#VisualAbstract: Prasinezumab therapy does not affect Parkinson’s Disease progression
1. Prasinezumab had no meaningful effect on global or imaging measures of Parkinson’s disease progression. 2. Prasinezumab therapy was associated ...
Tag: monoclonal antibody
#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
1. In coronavirus disease 2019 (COVID-19) patients, molnupiravir was associated with earlier and larger reductions of C-reactive protein (CRP) as ...
#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the casirivimab and imdevimab ...
Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the casirivimab and imdevimab ...
Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome
1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo. ...
Adjunctive nivolumab reduces risk of death and progression of gastric adenocarcinoma compared to chemotherapy alone
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...
#VisualAbstract: Avelumab does not improve outcomes in patients receiving chemoradiotherapy for squamous cell carcinomas of the head and neck
Click to read the study in The Lancet Oncology.
Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
#VisualAbstract: Margetuximab improves progression-free survival in patients with ERBB2⁺ advanced breast cancer compared to trastuzumab
Click to read the study in JAMA Oncology.
Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease
1. Patients who received AK002, lirentelimab, had far greater reductions in both gastrointestinal eosinophil burden and gastrointestinal symptoms compared to ...